PROCEPT BioRobotics (Nasdaq:PRCT) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

PRCT 주식 개요

수술용 로봇 회사인 PROCEPT BioRobotics Corporation은 미국 및 전 세계 비뇨기과 분야에서 혁신적인 솔루션을 개발하는 데 주력하고 있습니다.

PRCT 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	2/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

수익은 연간 24.45% 증가할 것으로 예상됩니다.

분석가들은 주가가 22.8% 상승할 것이라는 데 동의합니다.

위험 분석

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

지난 1년 동안 주주가 희석되었습니다.

PROCEPT BioRobotics Corporation 경쟁사

Inspire Medical Systems

NYSE:INSP

US$4.0b

Axonics

NasdaqGS:AXNX

US$3.4b

TransMedics Group

NasdaqGM:TMDX

US$5.0b

Inari Medical

NasdaqGS:NARI

US$2.8b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 PROCEPT BioRobotics
과거 주가
현재 주가	US$61.09
52주 최고치	US$77.00
52주 최저치	US$24.83
베타	1.04
11개월 변경	-8.00%
3개월 변경 사항	31.21%
1년 변경 사항	72.28%
33년 변화	n/a
5년 변화	n/a
IPO 이후 변화	45.66%

최근 뉴스 및 업데이트

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

May 21

Recent updates

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

May 21

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

Apr 05

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Mar 01

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Feb 07

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Dec 14

Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Feb 27

Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

May 10

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$41.00 Price Target

Mar 10

주주 수익률

	PRCT	US Medical Equipment	US 마켓
7D	4.1%	0.007%	-0.06%
1Y	72.3%	-1.4%	20.5%

수익률 대 산업: PRCT 지난 1년 동안 -0.5 %를 반환한 US Medical Equipment 산업을 초과했습니다.

수익률 대 시장: PRCT 지난 1년 동안 23.3 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is PRCT's price volatile compared to industry and market?
PRCT volatility
PRCT Average Weekly Movement	6.8%
Medical Equipment Industry Average Movement	8.2%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.9%

안정적인 주가: PRCT 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: PRCT 의 주간 변동성( 7% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2007	626	Reza Zadno	www.procept-biorobotics.com

수술용 로봇 회사인 PROCEPT BioRobotics Corporation은 미국 및 전 세계 비뇨기과 분야에서 혁신적인 솔루션을 개발하는 데 주력하고 있습니다. 이 회사는 양성 전립선 비대증(BPH) 치료에 중점을 두고 최소 침습 비뇨기과 수술에 사용되는 이미지 가이드 수술용 로봇 시스템인 아쿠아빔 로봇 시스템을 개발, 제조 및 판매합니다. 또한 BPH로 인해 하부 요로 증상을 겪는 남성을 위한 아쿠아블레이션 치료법도 설계합니다.

PROCEPT BioRobotics Corporation 기본 사항 요약

PROCEPT BioRobotics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
PRCT 기본 통계
시가총액	US$3.14b
수익(TTM)	-US$103.37m
수익(TTM)	US$156.33m

20.1x

P/S 비율

-30.4x

P/E 비율

PRCT 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
PRCT 손익 계산서(TTM)
수익	US$156.33m
수익 비용	US$72.73m
총 이익	US$83.59m
기타 비용	US$186.96m
수익	-US$103.37m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-2.01
총 마진	53.47%
순이익 마진	-66.12%
부채/자본 비율	20.2%

PRCT 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

PRCT 주식 개요

보상

위험 분석

PROCEPT BioRobotics Corporation 경쟁사

NYSE:INSP

US$4.0b

NasdaqGS:AXNX

US$3.4b

NasdaqGM:TMDX

US$5.0b

NasdaqGS:NARI

US$2.8b

가격 내역 및 성능

최근 뉴스 및 업데이트

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

PROCEPT BioRobotics Corporation Announces Long-Term, Real-World Data Showing the Benefits of Aquablation Therapy for the Treatment of Symptomatic Prostatic Hyperplasia

Independent Director notifies of intention to sell stock

Price target increased by 13% to US$65.00

Procept Biorobotics Corporation Increases Revenue Guidance for Full Year 2024

First quarter 2024 earnings released: US$0.51 loss per share (vs US$0.63 loss in 1Q 2023)

Recent updates

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

PROCEPT BioRobotics Corporation Announces Long-Term, Real-World Data Showing the Benefits of Aquablation Therapy for the Treatment of Symptomatic Prostatic Hyperplasia

Independent Director notifies of intention to sell stock

Price target increased by 13% to US$65.00

Procept Biorobotics Corporation Increases Revenue Guidance for Full Year 2024

First quarter 2024 earnings released: US$0.51 loss per share (vs US$0.63 loss in 1Q 2023)

PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 04, 2024

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

PROCEPT BioRobotics Corporation to Report Q1, 2024 Results on May 01, 2024

President recently sold US$263k worth of stock

Executive VP & CFO exercised options to buy US$2.6m worth of stock.

President recently sold US$428k worth of stock

Independent Director notifies of intention to sell stock

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Price target increased by 11% to US$56.67

PROCEPT BioRobotics Corporation Provides Revenue Guidance for the Full Year 2024

Full year 2023 earnings: EPS misses analyst expectations

Executive VP & CFO notifies of intention to sell stock

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Price target increased by 7.3% to US$51.17

Price target increased by 12% to US$50.33

Executive VP & CFO exercised options and sold US$702k worth of stock

PROCEPT BioRobotics Corporation to Report Q4, 2023 Results on Feb 27, 2024

Price target increased by 7.6% to US$47.17

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Independent Chairman of the Board recently sold US$3.1m worth of stock

Executive VP & CFO notifies of intention to sell stock

Price target decreased by 7.9% to US$40.67

Independent Director recently sold US$805k worth of stock

Independent Director notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

PROCEPT BioRobotics Corporation Revises Revenue Guidance for the Full Year 2023

PROCEPT BioRobotics Corporation to Report Q3, 2023 Results on Nov 01, 2023

Procept Biorobotics Corporation Receives U.S. Fda Investigational Device Exemption to Investigate Aquablation Therapy for Prostate Cancer

PROCEPT Biorobotics Corporation Announces First Commercial Aquablation Therapy Procedures in Japan

Price target decreased by 7.6% to US$47.29

PROCEPT BioRobotics Corporation has completed a Follow-on Equity Offering in the amount of $149.999972 million.

Insider exercised options and sold US$280k worth of stock

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

PROCEPT BioRobotics Corporation Revises Earnings Guidance for the Year 2023

PROCEPT BioRobotics Corporation to Report Q2, 2023 Results on Jul 27, 2023

Executive VP & CFO recently sold US$795k worth of stock

Insider exercised options to buy US$366k worth of stock.

First quarter 2023 earnings: EPS misses analyst expectations

President recently sold US$170k worth of stock

Executive VP & CFO recently sold US$1.0m worth of stock

Independent Director notifies of intention to sell stock

No longer forecast to breakeven

Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

PROCEPT BioRobotics Corporation to Report Q4, 2022 Results on Feb 28, 2023

Now 22% undervalued

High number of new directors

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

PROCEPT BioRobotics Corporation Projects Earnings Guidance for the Full Year 2022

Now 20% undervalued

PROCEPT BioRobotics Corporation to Report Q3, 2022 Results on Nov 03, 2022

Procept Biorobotics announces $52M debt refinancing

Providence announces national contract for PROCEPT Biorobotics Aquabeam Systems